Compare Quest Diagnostics Inc (DGX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Smith & Nephew plc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Quest Diagnostics Inc is far larger — about 2.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Smith & Nephew plc for 121 Days on average.
| DGX | SNN | |
|---|---|---|
Market Cap | $25.48B | $11.10B |
Volume | 941,866 | 1,051,703 |
Sector | Health | Health |
52-Week High | $247.45 | $37.17 |
52-Week Low | $173.49 | $26.42 |
Typical Hold Time | 56 Days | 121 Days |
Enterprise Value | $31.23B | $14.13B |
Dividend Yield | 1.49% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
